Fidaxomicin more cost effective than vancomycin in patients with cancer infected with clostridium difficile
the ONA take:
According to new research presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2014), patients with cancer who become infected with clostridium dificile would save about €5,600 per patient if treated with fidaxomicin compared with vancomycin, the current standard of care.
Clostridium dificile infection (CDI) can often present in patients received chemotherapy. In addition, those with solid cancers can be more susceptible to CDI than those with liquid tumors due to longer hospital admissions and increased antibiotic exposure and anti-cancer agents. When antibiotics alter a patient's gut flora and destroy many bacteria that live in the gut, clostridium dificile is given the chance to multiply and cause infection, thus causing diarrhea requiring antibiotics with gram-positive anaerobic coverage.
The most common agents used to treat CDI are metronidazole, oral vancomycin, and fidaxomicin, but treatment depends on severity of the infection. Multiple courses of oral vancomycin can be expensive for patients, and this decision-tree analysis demonstrates that fidaxomicin for the treatment of CDI in patients with cancer can reduce healthcare spending while maintaining effectiveness compared with vancomycin.
Those infected with clostridium dificile would save about €5,600 per patient if treated with fidaxomicin.
New data presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2014) show that overall treatment costs for cancer patients with clostridium difficile infection (CDI), based on a decision tree analysis, are lower with fidaxomicin compared to current standard of care, vancomycin, resulting in a potential cost saving of €5,600 per patient.
Patients who have received chemotherapy and those with solid tumours can be particularly susceptible to CDI due to their long hospital stays and exposure to many antibiotics and chemotherapeutic agents. These patients are also prone to recurrent episodes of CDI.
- More Than Half of Melanomas Are Self-Detected, Especially by Women
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
- POLST Programs Can Benefit from the Relationship Between Patients and Nurse Practitioners
- Olaratumab in Combo With Doxorubicin Approved for Soft Tissue Sarcoma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Adherence to Tamoxifen, AIs Among Older Women is Low, Study Shows
- Replacing Neoadjuvant CRT with Multiagent Chemo Not Recommended for Rectal Cancer
- Study Identifies Factors Associated With Infection-related Complications in ALL
- Immune Checkpoint-Related Neurotoxicity May Be More Common During Combination Treatment
- New Recommendations for Secondary Prevention of Cervical Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|